Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Ovarian Neoplasms

  Free Subscription


22.06.2026

2 Am J Surg Pathol
1 Br J Cancer
1 Eur J Obstet Gynecol Reprod Biol
6 Gynecol Oncol
1 Int J Gynaecol Obstet
6 Int J Gynecol Pathol
1 J Clin Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg Pathol

  1. MEANS AM, Lucas E, Zhang S, Rivera-Colon G, et al
    Endometrioid Intraepithelial Neoplasia in the Secretory Phase: Morphologic and Biomarker Diagnostic Features in a Common, Overlooked Setting.
    Am J Surg Pathol. 2026 Apr 13. doi: 10.1097/PAS.0000000000002548.
    PubMed         Abstract available

  2. ZYLA RE, Howitt BE, Bosse T, van Slooten FE, et al
    GLI1 -Rearranged Tumors of the Gynecologic Tract : A Detailed Clinicopathologic Study of 10 Cases.
    Am J Surg Pathol. 2026;50:804-813.
    PubMed         Abstract available


    Br J Cancer

  3. LANGE JM, Ahmad I, Dengos IJ, Ryan A, et al
    Can ovarian cancer screening work? A secondary analysis of the UK collaborative trial of ovarian cancer screening.
    Br J Cancer. 2026 Jun 13. doi: 10.1038/s41416-026-03490.
    PubMed         Abstract available


    Eur J Obstet Gynecol Reprod Biol

  4. PARIC A, Tomic K, Begagic E, Naletilic MP, et al
    The prognostic and decision-making impact of KELIM CA-125 in patients with advanced ovarian cancer: A real-world study from Bosnia and Herzegovina.
    Eur J Obstet Gynecol Reprod Biol. 2026;324:115245.
    PubMed         Abstract available


    Gynecol Oncol

  5. JAMIESON A, Kwon J, Gao T, Lee J, et al
    Assessing the essential parameters of race, ethnicity and geography in endometrial cancer and the impact on presentation, treatment and outcomes.
    Gynecol Oncol. 2026;209:158-166.
    PubMed         Abstract available

  6. GAILLARD S, Parker J, Broadwater G, Duska L, et al
    Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.
    Gynecol Oncol. 2026;210:208-216.
    PubMed         Abstract available

  7. ALASHQAR A, Clark M, Gross CP, Spatz ES, et al
    Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study.
    Gynecol Oncol. 2026;211:17-22.
    PubMed         Abstract available

  8. LEE J, Seo K, Kim J, Son JH, et al
    Corrigendum to "Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer" [Volume 208, May 2026, Pages 85-90].
    Gynecol Oncol. 2026;211:8.
    PubMed        

  9. BERGERON AM, Kisiel M, Lavecchia M, Mah S, et al
    Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?
    Gynecol Oncol. 2026;211:23-28.
    PubMed         Abstract available

  10. SULEIMAN R, Mokshagundam S, Block MS, Wahner Hendrickson AE, et al
    Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.
    Gynecol Oncol. 2026;211:9-16.
    PubMed         Abstract available


    Int J Gynaecol Obstet

  11. FANAKI M, Kordali T, Thomakos N, Vlachos DE, et al
    Postoperative decline in CA-125 as a prognostic biomarker in ovarian cancer: A systematic review and meta-analysis.
    Int J Gynaecol Obstet. 2026 Jun 19. doi: 10.1002/ijgo.71146.
    PubMed         Abstract available


    Int J Gynecol Pathol

  12. HUVILA J, Gilks CB, McAlpine JN, Jamieson A, et al
    Coexistent Endometrial and Ovarian Carcinoma: Terminology, Clinicopathological Features, and Clinical Significance.
    Int J Gynecol Pathol. 2026;45:304-310.
    PubMed         Abstract available

  13. TOMITA M, Horiguchi H, Saijo Y, Maeda Y, et al
    A Case of Ovarian Seromucinous Borderline Tumor With a Predominant Serous Component Suggesting Serous Borderline Tumor With Mucinous Differentiation.
    Int J Gynecol Pathol. 2026;45:318-322.
    PubMed         Abstract available

  14. NIU S, Molberg K, Carrick K, Colon GR, et al
    Endometrioid Versus Seromucinous Borderline Ovarian Tumors: Divergent Molecular Signatures and a Shared Role as Precursors to Endometrioid Carcinoma.
    Int J Gynecol Pathol. 2026;45:253-261.
    PubMed         Abstract available

  15. ZEIDEL A, Cole L
    Glandular Crowding of the Endometrium: Clinical Outcomes of a Diagnostic Gray Zone.
    Int J Gynecol Pathol. 2026;45:291-296.
    PubMed         Abstract available

  16. KAJIYAMA H, Kashima Y, Otani T, Sakai K, et al
    Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation.
    Int J Gynecol Pathol. 2026;45:311-317.
    PubMed         Abstract available

  17. MALYI A, Toth E, Vereczkey I, Kohanka A, et al
    Papillary Thyroid Carcinoma With an STRN::ALK Fusion Arising From a Mature Ovarian Teratoma.
    Int J Gynecol Pathol. 2026;45:323-327.
    PubMed         Abstract available


    J Clin Oncol

  18. BERGAMINI A, Suyanto S, Savva C, Maher E, et al
    Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.
    J Clin Oncol. 2026;44:1720-1729.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum